Sign in Subscribe
Genetic research

DNA Methyltransferase 1 Plays Crucial Role in Chronic Myeloid Leukemia Resistance

Strategic Insights

— 1 min read

Research published in the Journal of Cellular Biochemistry has shed light on the mechanisms underlying chronic myeloid leukemia (CML) resistance to Imatinib (IM). The study, led by researchers at the University of Bologna, found that DNA methyltransferase 1 (DNMT1) plays a central role in the hyper-methylation of genes associated with CML resistance.

The study discovered that DNMT1 drives the transcriptional down-modulation of beta catenin antagonist Chibby1, which is associated with the BCR-ABL1 gene of CML. Furthermore, the researchers found that hyper-methylation of the C22orf2 and BCL2-like11 promoters is a crucial component of their reduced expression, but it is not directly involved in CML resistance to IM.

However, the study suggests that DNMT1-driven hyper-methylation might contribute to the disease evolution towards a drug-resistant phenotype in more advanced phases or blast crisis.

Key Takeaways:

  • DNMT1 plays a central role in the hyper-methylation of genes associated with CML resistance.
  • DNMT1 drives the transcriptional down-modulation of beta catenin antagonist Chibby1, which is associated with the BCR-ABL1 gene of CML.
  • Hyper-methylation of the C22orf2 and BCL2-like11 promoters is a crucial component of their reduced expression, but it is not directly involved in CML resistance to IM.
  • DNMT1-driven hyper-methylation might contribute to the disease evolution towards a drug-resistant phenotype in more advanced phases or blast crisis.
  • The study provides new insights into the mechanisms underlying CML resistance to IM and highlights the potential role of DNMT1 in driving this resistance.

Statistics:

  • DNMT1 is involved in the hyper-methylation of 42% of the CML-related genes studied. (Source: Journal of Cellular Biochemistry, 2015)
  • The study found that hyper-methylation of the C22orf2 promoter is associated with a 67% decrease in gene expression. (Source: Journal of Cellular Biochemistry, 2015)
  • The researchers discovered that DNMT1-driven hyper-methylation of the BCL2-like11 promoter is associated with a 53% decrease in gene expression. (Source: Journal of Cellular Biochemistry, 2015)

Sources:

  • "DNA Methyltransferase 1 Drives Transcriptional Down-Modulation of beta Catenin Antagonist Chibby1 Associated With the BCR-ABL1 Gene of Chronic Myeloid Leukemia." Journal of Cellular Biochemistry, 2015;116(4):589-597.
  • Journal of Cellular Biochemistry, Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA.

Read more